A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Recruiting

Phase 2

Talazoparib & EnzalutamideA Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Sponsor:

Prostate Cancer Clinical Trials Consortium

Code:

NCT06844383

Conditions

Prostate Cancer (Adenocarcinoma)

mCRPC (Metastatic Castration-resistant Prostate Cancer)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talazoparib with enzalutamide

Talazoparib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-05. This information was provided to ClinicalTrials.gov by Prostate Cancer Clinical Trials Consortium on 2025-10-29.